|
Fetal Alcohol Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis.
|
29109170 |
2018 |
|
Alcohol Related Neurodevelopmental Disorder
|
0.300 |
Biomarker
|
disease |
CTD_human |
L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis.
|
29109170 |
2018 |
|
Fetal Alcohol Spectrum Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis.
|
29109170 |
2018 |
|
Alcohol Related Birth Defect
|
0.300 |
Biomarker
|
disease |
CTD_human |
L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis.
|
29109170 |
2018 |
|
Partial Fetal Alcohol Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis.
|
29109170 |
2018 |
|
Sezary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
|
26551670 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.110 |
Biomarker
|
disease |
BEFREE |
Thus, RSK1 represents a promising target, particularly in combination with PIM or PI3K, as well as anti-apoptotic Bcl-2 family members, for novel therapeutic strategies against therapy-resistant FLT3-ITD-positive AML.
|
31756944 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study identifies novel recessive genetic variants for high TGs in an Arab population.
|
30108155 |
2018 |
|
Mean Corpuscular Volume (result)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
We found that RSK1 promoted tumor growth and metastasis in vivo.
|
29498411 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Finally, <i>in vivo</i> studies revealed that the hormone activates RSK in xenografts tumor.
|
28385776 |
2017 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Mechanistically, downregulation of HERV-K blocked expression of tumor-associated genes that included Ras, p-RSK, and p-ERK.
|
27557521 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The p90RSK has an essential role in promoting tumor growth and proliferation in non-small cell lung cancer (NSCLC).
|
27236820 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The K17-hnRNP K partnership is regulated by the ser/thr kinase RSK and required for CXCR3-dependent tumor cell growth and invasion.
|
25713416 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Several studies implicate the RSK pathway as being pivotal for the growth and proliferation of CSCs, which are postulated to drive tumor relapse.
|
26011941 |
2015 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In paraffin-embedded, formalin-fixed tissues from core needle biopsy tissues from 112 patients, positive phospho-p90RSK expression was associated with greater tumor shrinkage and smaller post-chemotherapy tumor size.
|
23216670 |
2012 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
While in lung and other tumors RSK may control apoptosis via estrogen-mediated regulation of mitochondrial integrity.
|
20045011 |
2010 |
|
Neoplasms
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
RSK1 phosphorylation of Ser-1798 inhibits the tumor suppressor function of the tuberin/hamartin complex, resulting in increased mTOR signaling to S6K1.
|
15342917 |
2004 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
RSK1 promotes murine breast cancer growth and metastasis.
|
29498411 |
2018 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
These findings establish RSK2 as an obligate participant of ERα-mediated transcriptional programs, tumorigenesis, and divergent patient responses to antiestrogen therapies.<b>Significance:</b> Nuclear accumulation of active RSK drives a protumorigenic transcriptional program and renders ER<sup>+</sup> breast cancer susceptible to endocrine-based therapies.<i>Cancer Res; 78(8); 2014-25.©2018 AACR</i>.
|
29351904 |
2018 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
RSK1 promotes murine breast cancer growth and metastasis.
|
29498411 |
2018 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Although the RSKs have a high degree of sequence homology, their functional differences in cancer are of great interest.
|
28718440 |
2017 |